REG - Immupharma PLC - Appointments of CSO and Head of R&D

ImmuPharmaAnnouncement

01/09/2025 14:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250901:nRSA5047Xa&default-theme=true

RNS Number : 5047X  Immupharma PLC  01 September 2025

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

 

Appointments of Chief Scientific Officer and Head of R&D

 

ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics, announces key appointments,
in conjunction with the filing of a groundbreaking new patent application for
its lead asset P140, separately announced today.

 

Recognising the significance of this major step forward, Dr Sébastien
Goudreau has been promoted into the position of Chief Scientific Officer and
Dr Laura Mauran-Ambrosino has been promoted to Head of Research and
Development, of the Company.

 

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:

"The new patent on P140 is a major step forward for the Company and is the
result of the impressive and dedicated research conducted by both by
Sébastien and Laura over the last two years.

 

 As we continue to move forward on the next step of our corporate journey,
which is the partnering and commercialisation of our product portfolio, P140
in particular, it is important that our R&D team is at the forefront of
our interactions and negotiations with current and future commercial partners.

 

I and the Board congratulate both Sébastien and Laura on their new
appointments and thank them for their innovation and hard work."

 

 

Ends

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

 

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(https://www.immupharma.co.uk/) .

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEADNFEEXSEFA